(18.97.14.90)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 10
First page : ( 4621) Last page : ( 4624)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00813.6

Impact of Salbutamol in Chronic Obstructive Pulmonary Diseases patients: A prospective observational study on Clinical interventions

Meena S. Sandhoshini1, Somasundaram I.2*

1Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Pallavaram, Chennai - 600117, Tamil Nadu, India

2Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Pallavaram, Chennai - 600117, Tamil Nadu, India

*Corresponding Author E-mail: somous0926@gmail.com

Online published on 28 October, 2020.

Abstract

This study aimed to investigate the short-term effects of salbutamol in Chronic obstructive pulmonary disease (COPD) patients and to assess the incidence of Hyperglycemia and Tachycardia. The study is a Prospective, observational study conducted in Department of General Medicine on a sample of 136 COPD patients. After administration of Nebulised salbutamol, the Heart Rate and Random Blood Sugar (RBS) levels of patients were assessed in two periods; baseline and after 24 hour. The Random Blood Sugar mean was significantly increased after 24 hour of nebulizer administration (p<0.0001). The Heart Rate mean was significantly increased after 24 hour of nebulizer administration (p<0.0001). The nebulizer applying salbutamol has a profound effect in increasing the Random Blood Sugar level and Heart Rate after 24 hours of administration.

Top

Keywords

Salbutamol, Hyperglycemia, Tachycardia, Random blood sugar, Heart Rate.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
853,773,003 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.